Abstract
Although the underlying mechanisms are not well understood, it is generally believed that antigen recognition by T cells in the absence of costimulation may alter the immune response, leading to anergy or tolerance. Further support for this concept comes from animal models of autoimmunity and transplantation, where treatments based on costimulation blockade, in particular CD40 ligand (CD40L)-specific antibodies, have been highly effective. We investigated the mechanisms of action of an antibody to CD40L and provide evidence that its effects are dependent on the constant (Fc) region. Prolongation of graft survival is dependent on both complement- and Fc receptor–mediated mechanisms in a major histocompatibility complex (MHC)-mismatched skin transplant model. These data suggest that antibodies to CD40L act through selective depletion of activated T cells, rather than exerting immune modulation by costimulation blockade as currently postulated. This finding opens new avenues for treatment of immune disorders based on selective targeting of activated T cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Grewal, I.S. & Flavell, R.A. The role of CD40 ligand in costimulation and T-cell activation. Immunol. Rev. 153, 85–106 (1996).
Grewal, I.S. & Flavell, R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16, 111–135 (1998).
Kirk, A.D. et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat. Med. 5, 686–693 (1999).
Hancock, W.W. Current trends in transplant immunology. Curr. Opin. Nephrol. Hypertens. 8, 317–324 (1999).
Gudmundsdottir, H. & Turka, L.A. T cell costimulatory blockade: new therapies for transplant rejection. J. Am. Soc. Nephrol. 10, 1356–1365 (1999).
Waldmann, H. Transplantation tolerance-where do we stand? Nat. Med. 5, 1245–1248 (1999).
Jenkins, M.K., Pardoll, D.M., Mizuguchi, J., Quill, H. & Schwartz, R.H. T-cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol. Rev. 95, 113–135 (1987).
Schwartz, R.H. A cell culture model for T lymphocyte clonal anergy. Science 248, 1349–1356 (1990).
Matzinger, P. Graft tolerance: a duel of two signals. Nat. Med. 5, 616–617 (1999).
Larsen, C.P. et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434–438 (1996).
Kirk, A.D. et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA 94, 8789–8794 (1997).
Van den Eertwegh, A.J. et al. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions. J. Exp. Med. 178, 1555–1565 (1993).
Foy, T.M. et al. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory. J. Exp. Med. 180, 157–163 (1994).
Xu, J. et al. Mice deficient for the CD40 ligand. Immunity 1, 423–431 (1994).
Whitmire, J.K., Slifka, M.K., Grewal, I.S., Flavell, R.A. & Ahmed, R. CD40 ligand-deficient mice generate a normal primary cytotoxic T- lymphocyte response but a defective humoral response to a viral infection. J. Virol. 70, 8375–8381 (1996).
Greenfield, A. et al. An H-YDb epitope is encoded by a novel mouse Y chromosome gene. Nat. Genet. 14, 474–478 (1996).
Simpson, E., Scott, D. & Chandler, P. The male-specific histocompatibility antigen, H-Y: a history of transplantation, immune response genes, sex determination and expression cloning. Annu. Rev. Immunol. 15, 39–61 (1997).
Millrain, M. et al. Examination of HY response: T cell expansion, immunodominance, and cross-priming revealed by HY tetramer analysis. J. Immunol. 167, 3756–3764 (2001).
Kawai, T., Andrews, D., Colvin, R.B., Sachs, D.H. & Cosimi, A.B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 6, 114 (2000).
Illei, G.G. & Lipsky, P.E. Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases. Curr. Opin. Immunol. 12, 712–718 (2000).
Dharnidharka, V.R., Schowengerdt, K. & Skoda-Smith, S. Failure of combined costimulatory blockade in animal transplant model. Nat. Med. 6, 115 (2000).
Li, Y. & Strom, T.B. Reply to failure of combined costimulatory blockade in animal transplant model. Nat. Med. 6, 115 (2000).
Houghton, A.N. & Scheinberg, D.A. Monoclonal antibody therapies-a 'constant' threat to cancer. Nat. Med. 6, 373–374 (2000).
Clynes, R.A., Towers, T.L., Presta, L.G. & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6, 443–446 (2000).
Pacheco-Silva, A. et al. Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. Eur. J. Immunol. 22, 697–702 (1992).
Strom, T.B., Kelley, V.R., Murphy, J.R., Nichols, J. & Woodworth, T.G. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules. Annu. Rev. Med. 44, 343–353 (1993).
Zheng, X.X. et al. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J. Immunol. 163, 4041–4048 (1999).
Graca, L., Honey, K., Adams, E., Cobbold, S.P. & Waldmann, H. Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance. J. Immunol. 165, 4783–4786 (2000).
Wells, A.D. et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5, 1303–1307 (1999).
Li, X.C., Wells, A.D., Strom, T.B. & Turka, L.A. The role of T cell apoptosis in transplantation tolerance. Curr. Opin. Immunol. 12, 522–527 (2000).
Ferguson, T.A. & Green, D.R. T cells are just dying to accept grafts. Nat. Med. 5, 1231–1232 (1999).
Wells, A.D., Li, X.C., Strom, T.B. & Turka, L.A. The role of peripheral T-cell deletion in transplantation tolerance. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356, 617–623 (2001).
Mach, F. et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. USA 94, 1931–1936 (1997).
Smiley, S.T., Csizmadia, V., Gao, W., Turka, L.A. & Hancock, W.W. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction. Transplantation 70, 415–419 (2000).
Iwakoshi, N.N. et al. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J. Immunol. 164, 512–521 (2000).
Durham, M.M. et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J. Immunol. 165, 1–4 (2000).
Lane, P., Gerhard, W., Hubele, S., Lanzavecchia, A. & McConnell, F. Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA4 and human gamma 1. Immunology 80, 56–61 (1993).
Wessels, M.R. et al. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA 92, 11490–11494 (1995).
Zhou, W. et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J. Clin. Invest. 105, 1363–1371 (2000).
Park, S.Y. et al. Resistance of Fc receptor- deficient mice to fatal glomerulonephritis. J. Clin. Invest. 102, 1229–1238 (1998).
Marsh, J.E. et al. The allogeneic T and B cell response is strongly dependent on complement components C3 and C4. Transplantation 72, 1310–1318 (2001).
Lane, P., Burdet, C., McConnell, F., Lanzavecchia, A. & Padovan, E. CD40 ligand-independent B cell activation revealed by CD40 ligand- deficient T cell clones: evidence for distinct activation requirements for antibody formation and B cell proliferation. Eur. J. Immunol. 25, 1788–1793 (1995).
Altman, J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94–96 (1996).
Acknowledgements
We thank P. Lane for providing us with CD40L transfectants, M. Allen for advice and help with rapamycin supply, M. Goggin for large-scale antibody production, and D. Gray and members of the Sacks and Simpson laboratories for their helpful advice and comments. This work was supported by the Wellcome Trust, Guy's & Saint Thomas' Charitable Foundation and the Medical Research Council UK.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Monk, N., Hargreaves, R., Marsh, J. et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med 9, 1275–1280 (2003). https://doi.org/10.1038/nm931
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm931
This article is cited by
-
T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway
Cellular & Molecular Immunology (2017)
-
Targeting co-stimulatory pathways: transplantation and autoimmunity
Nature Reviews Nephrology (2014)
-
The role of complement in the early immune response to transplantation
Nature Reviews Immunology (2012)
-
From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis
Nature Genetics (2010)
-
Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy
Cancer Immunology, Immunotherapy (2010)